Nina Casanova, MD
Urology · Denver, CONPI 1447471602
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,105 of the $11,590 with a category attached, or 61.3%. Coloplast accounts for 80.8% of it on its own, with 18 other manufacturers making up the rest. 2025 is the largest year on record at $7,610, more than ten times the $137 reported in 2019.
Across 98 payments — averaging $118.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$9K
- Teleflex LLC$408
- Boston Scientific$332
- Palette Life Sciences, Inc.$291
- Ambu Inc.$183
- Astellas Pharma US Inc$166
- plus $851 from 13 others
What the payments were for
- Consulting fees$7,10561%
- Travel & lodging$4584%
- Food & beverage$3,83833%
- Education$1892%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 45 | $9,359 |
| Teleflex LLC | 4 | $408 |
| Boston Scientific | 7 | $332 |
| Palette Life Sciences, Inc. | 2 | $291 |
| Ambu Inc. | 3 | $183 |
| Astellas Pharma US Inc | 4 | $166 |
| Axonics, Inc. | 5 | $151 |
| Neotract Inc. | 1 | $95 |
| Sumitomo Pharma America, Inc. | 4 | $94 |
| Laborie Medical Technologies Corp. | 5 | $85 |
| Innovation Technologies Inc | 2 | $80 |
| AbbVie | 4 | $77 |
| 180 Medical, Inc. | 3 | $69 |
| Urovant Sciences Inc | 3 | $62 |
| Procept Biorobotics Corporation | 2 | $51 |
| Pfizer | 1 | $29 |
| Myovant Sciences Inc. | 1 | $24 |
| Medtronic | 1 | $17 |
| Hollister Incorporated | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ALTIS$7,948
- UroLift System$284
- ADVANTAGE FIT$221
How this compares
$11,590 in reported general payments places this provider in the 80th percentile of 225 urology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 152 | $157,852 |
| GemtesaVibegron | 127 | $112,131 |
| Estradiol | 134 | $10,541 |
| Potassium Citrate ErPotassium Citrate | 61 | $5,013 |
| Solifenacin Succinate | 117 | $4,785 |
| Tamsulosin Hcl | 216 | $3,614 |
| Methenamine Hippurate | 44 | $3,236 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 36 | $2,812 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 90 | $2,717 |
| Oxybutynin Chloride ErOxybutynin Chloride | 108 | $2,352 |
| NitrofurantoinNitrofurantoin Macrocrystal | 29 | $1,728 |
| Finasteride | 55 | $1,133 |
| Cefdinir | 46 | $1,047 |
| Silodosin | 14 | $960 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 118 | $692 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $166 | $157,852152 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $94 | $112,131127 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 225 urology providers in Colorado.
Other urology in Denver
- Lawrence KarshDenver$706K
- Elizabeth SnyderDenver$53K
- Juan MontoyaDenver$50K
- Elias HsuDenver$23K
- John TillettDenver$21K
- Milford PainterDenver$13K
- Julien DagenaisDenver$11K
- Stephen RuyleDenver$9K
- Brian SmithDenver$8K
- Richard HeppeDenver$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.